Coagulation defects in neonates during cardiopulmonary bypass.
We examined components of the coagulation system in 30 neonates (age, 1 to 30 days) undergoing deep hypothermic cardiopulmonary bypass (CPB). A coagulation profile consisting of activated clotting time; prothrombin time; partial thromboplastin time; factors II, V, VII, VIII, IX, X, and I (fibrinogen); antithrombin III; platelet count; and heparin levels was evaluated before bypass, at three intervals during bypass (1 minute after initiation of bypass, stable hypothermic CPB, warm CPB), after weaning from CPB and administration of protamine, and 2 to 3 hours after skin closure. The initiation of CPB resulted in a 50% decrease in circulating coagulation factors and antithrombin III levels. Platelet counts were reduced by 70% with CPB initiation. Neither deep hypothermic temperatures nor prolonged exposure to extracorporeal surfaces had any additional effect on the coagulation profiles. This suggests that the coagulation system of a neonate undergoing CPB is profoundly and globally effected by hemodilution. We believe that treatment of post-CPB coagulopathy in neonates must address these global deficits.
Kern
F H
FH
Department of Anesthesiology, Children's Hospital, Boston, Massachusetts.
Morana
N J
NJ
Sears
J J
JJ
Hickey
P R
PR
D000990:Antithrombin III / Q000032:analysis; D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology*; D001779:Blood Coagulation Factors / Q000032:analysis; D001831:Body Temperature; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D005340:Fibrinogen / Q000032:analysis; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D007231:Infant, Newborn; D010976:Platelet Count; D011479:Protamines / Q000008:administration & dosage
D001779:Blood Coagulation Factors; D011479:Protamines; D000990:Antithrombin III; D005340:Fibrinogen